#United States #Cambridge #Marengo Therapeutics #Invikafusp Alfa #STARt-001

Marengo Therapeutics Announces Groundbreaking Publication in Nature Medicine

In a significant development for cancer treatment, Marengo Therapeutics, a clinical-stage biotechnology company, has announced the publication of results from their STARt-001 Phase 1/2 clinical trial in the esteemed journal Nature Medicine. This represents a crucial milestone in establishing the first-in-human proof of Vβ-directed T-cell biology and its potent antitumor activity.

The STARt-001 trial investigated the effects of invikafusp alfa, a bispecific dual T-cell agonist, on patients suffering from advanced solid tumors that have been heavily pretreated and are resistant to immune checkpoint blockade therapies. This trial marks the first demonstration in humans that germline-encoded Vβ T-cell subsets can be selectively activated, leading to the expansion of functional effector and memory populations that can exert antitumor effects.

Key Findings from the Trial

The findings from the trial were nothing short of promising. The trial exhibited a manageable safety profile while providing evidence that invikafusp alfa could enhance the expansion of Vβ6/Vβ10 T cells in both peripheral and intratumoral environments. Notably, this therapy demonstrated objective responses across a variety of challenging tumor types, including those often resistant to previous treatments, such as microsatellite-stable colorectal cancer and PD-L1-negative non-small cell lung cancer.

Dr. Lillian L. Siu, a leading medical oncologist and co-author of the study, expressed optimism regarding the potential of this approach in combating advanced cancer. She stated, “These data provide encouraging clinical evidence that selected Vβ6/Vβ10 T-cell populations can be activated and expanded in patients with advanced cancer.”

The analysis confirmed that the Phase 1 dosage escalations were completed without reaching a maximum tolerated dose, leading to the identification of a recommended Phase 2 dosing strategy. This was based on consolidated safety and pharmacodynamic activity data, further reinforcing the therapy's viability.

The Mechanism of Invikafusp Alfa

Invikafusp alfa works by selectively activating a common subset of Vβ T-cells that are consistently present across various cancer types. This novel therapeutic target does not rely on specific tumor mutations, making it more versatile in treating diverse cancer forms. By combining T-cell receptor activation with co-stimulatory signals, invikafusp alfa is designed to amplify the immune response against tumors, particularly those resistant to existing therapies.

These groundbreaking results not only validate the existing hypotheses around Vβ-directed therapies but also lay the groundwork for extensive further explorations. Marengo's dedication to their innovative STAR, TriSTAR, and MSTAR platforms aims to redefine treatment approaches by selectively targeting the T-cells that can most effectively combat cancer.

Future Directions

As part of their ongoing research, Marengo plans to present interim results from the STARt-002 study at the upcoming SITC 2026 Annual Meeting, focusing on the combination of a Vβ6-selective T-cell agonist with an antibody-drug conjugate. This study aims to shed further light on how such combinatory therapies can combat triple-negative and other metastatic breast cancers.

Dr. Zhen Su, President and CEO of Marengo Therapeutics, highlighted the significance of these findings, saying, “For the first time, we demonstrate that selected germline Vβ T-cell populations can be therapeutically modulated in cancer patients.” The publication marks an essential transition from theoretical concepts into clinically validated methodologies, showcasing the immense potential of invikafusp alfa as a therapeutic tool against otherwise treatment-resistant cancers.

Conclusion

The publication in Nature Medicine signifies a breakthrough not just for Marengo Therapeutics, but for the field of oncology at large. By unveiling a novel approach to immunotherapy that shows promise across a diverse range of cancers, Marengo is paving the way for the next generation of precision cancer therapies,

As clinical trials progress and more data become available, the implications of this research could be transformative for patients grappling with hard-to-treat cancers, fostering hope in an area where options have traditionally been limited.